Malinowski Jennifer M, Metka Kimberly
Nesbitt School of Pharmacy and Nursing, Wilkes University, Wilkes-Barre, PA 18766, USA.
Ann Pharmacother. 2007 Jul;41(7):1296-300. doi: 10.1345/aph.1H695. Epub 2007 Jul 3.
To report a case of elevated low-density lipoprotein cholesterol (LDL-C) concentration in a patient taking fish oil supplements for hypertriglyceridemia.
A 63-year-old white woman had been taking 2.7 g of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily in 9 g of over-the-counter (OTC) fish oil capsules for triglyceride lowering. Prior to the adverse event, she had baseline fasting triglyceride (TG) and LDL-C concentrations of 278 mg/dL and 106 mg/dL, respectively. After 6 weeks of treatment with fish oil, fasting TG levels decreased by 47.5% (-132 mg/dL) and the LDL-C increased by 75% (+80 mg/dL). Discontinuation of therapy for 6 weeks resulted in TG returning to high concentrations (334 mg/dL; +56 mg/dL change from baseline) and LDL-C decreasing toward baseline (143 mg/dL; +37 mg/dL change from baseline).
Fish oil, an omega-3 polyunsaturated fatty acid, consists of EPA and DHA. EPA and DHA are thought to inhibit the synthesis of triglycerides in the liver. Type IV dyslipidemic patients may develop increased LDL-C levels while taking fish oil to lower triglycerides due to possible down-regulation of the LDL-C receptor in hepatic cells and formation of larger LDL particles. Use of the Naranjo probability scale indicates a probable relationship between elevations in LDL-C from baseline and initiation of fish oil treatment for hypertriglyceridemia. It is unknown whether any component within this particular product could have contributed to such an unusual elevation in LDL-C.
This case documents a much higher LDL-C elevation associated with OTC fish oil supplementation than has been previously identified in the literature. Healthcare providers should be advised that LDL-C levels may increase with use of OTC fish oil and should monitor patients periodically for such elevations. The significance of this increase on clinical outcomes is not known.
报告一例服用鱼油补充剂治疗高甘油三酯血症的患者出现低密度脂蛋白胆固醇(LDL-C)浓度升高的病例。
一名63岁的白人女性每天服用9克非处方(OTC)鱼油胶囊,其中含有2.7克二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)以降低甘油三酯。在出现不良事件之前,她的基线空腹甘油三酯(TG)和LDL-C浓度分别为278毫克/分升和106毫克/分升。服用鱼油治疗6周后,空腹TG水平下降了47.5%(-132毫克/分升),而LDL-C升高了75%(+80毫克/分升)。停药6周导致TG恢复到高浓度(334毫克/分升;较基线变化 +56毫克/分升),LDL-C降至基线水平(143毫克/分升;较基线变化 +37毫克/分升)。
鱼油是一种ω-3多不饱和脂肪酸,由EPA和DHA组成。EPA和DHA被认为可抑制肝脏中甘油三酯的合成。IV型血脂异常患者在服用鱼油降低甘油三酯时,可能会出现LDL-C水平升高,这可能是由于肝细胞中LDL-C受体可能下调以及形成更大的LDL颗粒。使用Naranjo概率量表表明,LDL-C从基线升高与开始使用鱼油治疗高甘油三酯血症之间可能存在关联。尚不清楚该特定产品中的任何成分是否导致了LDL-C如此异常的升高。
该病例记录了与OTC鱼油补充剂相关的LDL-C升高幅度远高于先前文献中所报道的情况。应告知医疗保健提供者,使用OTC鱼油可能会使LDL-C水平升高,并应定期监测患者的此类升高情况。这种升高对临床结局的意义尚不清楚。